eligibility_summary
Adults ≥18 with recurrent/metastatic HNSCC not amenable to curative local therapy, PD‑L1 CPS, ECOG 0–1, measurable disease, adequate labs, tissue. Cohort A: PD‑L1 ≥1, no prior systemic RM therapy (periop PD‑1 ok if DFI ≥6 mo). Cohort B: 1–2 prior RM lines incl anti‑PD1, progressed/intolerant. Exclude: recent therapy, active CNS, bleeding/autoimmune, CD47/SIRPα, immunosuppression/transplant, uncontrolled infection, pregnancy, hypersensitivity.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II (terminated) trial in recurrent/metastatic HNSCC. Cohort A: magrolimab + cetuximab + pembrolizumab. Cohort B: magrolimab + cetuximab + docetaxel. Drugs/mechanisms: • Magrolimab—anti-CD47 monoclonal antibody (IgG4), blocks CD47–SIRPα “don’t‑eat‑me” signal to promote macrophage phagocytosis (ADCP) of tumor cells. • Cetuximab—anti‑EGFR monoclonal antibody (IgG1), inhibits EGFR signaling (RAS/RAF/MEK/ERK, PI3K/AKT) and mediates NK‑cell ADCC. • Pembrolizumab—anti‑PD‑1 monoclonal antibody (IgG4), releases checkpoint inhibition to reinvigorate cytotoxic T cells. • Docetaxel—taxane chemotherapy, stabilizes microtubules causing mitotic arrest and immunogenic cell death. Targets: CD47/SIRPα axis (macrophages, tumor cells), EGFR pathway (tumor cells, NK via FcγR), PD‑1/PD‑L1 axis (T cells), and microtubules/mitosis.